Introduction {#sec1_1}
============

18F-fluciclovine (FCV) is a positron emission tomography (PET) radiopharmaceutical used for the detection of recurrent prostate cancer in adult men after primary curative treatment with the suspicion of recurrence based on elevated prostate-specific antigen (PSA) level \[[@B1]\]. The sensitivity of 18F-FCV PET for detecting recurrent disease increases with rising levels of PSA \[[@B2]\], the specificity for prostate bed in recurrent disease being 40--75%, as the residual prostate gland tissue is prone to uptake due to inflammation or prostatic hypertrophy, the specificity for extraprostatic lesions was reported 97 and 100% \[[@B1], [@B3], [@B4]\]. FCV is accumulated by prostate cancer cells via specialised amino acids transporters, predominantly alanine-serine-cysteine transporter 2 (ASCT2) with contribution of l-amino acid transporter 1 (LAT-1) \[[@B1]\].

The fact that 18F-FCV can be accumulated by other cancer types is stated in the radiopharmaceutical information, however, these are not specified. Several incidental uptakes of 18F-FCV have been described − in male breast cancer, hepatocellular carcinoma, and malignant melanoma \[[@B5], [@B6], [@B7]\]. Accumulation of 18F-FCV in lesions other than cancer was described in superior sagittal sinus due to its dilatation \[[@B8]\].

Case Presentation {#sec1_2}
=================

We present a case of a 78-year-old patient with a history of prostate cancer (February 2013: acinar adenocarcinoma, Gleason Score 3+3, T1cN0M0, PSA 7.91), who was treated by curative radiotherapy (June--September 2013, 78 Gy/39 fractions) with the following restaging examinations without any signs of relapse, the PSA trend: 1.14 (2014), 0.42 (2015), 0.47 (2016), 0.5 (2017), 0.3 (2018).

In 2018, the patient was admitted to our hospital for haemoptysis. The chest X-ray did not show any pathology; however, videofibrobronchoscopy proved a tumour in bronchopulmonary segment 10 on the left. The histological examination proved parts of bronchial mucosa with fragments of adenocarcinoma, with conclusion on a high suspicion of metastasis of acinar adenocarcinoma of the prostate gland. The CT scan proved a lung tumour in segment 10 on the left, several suspicious nodules in the left hilus, several liver metastases, and numerous osteoplastic bone metastases.

In October 2018, the patient underwent 18F-FCV PET with the following results: sclerotic metastatic lesions with higher accumulation of FCV in thoracic vertebrae 4 and 7, first sacral vertebra, and in the left ilium; tumorous lesion in the left lung obturating bronchi to segments 9 and 10 with higher cumulation of FCV (Fig. [1, left](#F1){ref-type="fig"}); three liver metastases, two of them with higher cumulation of FCV (Fig. [1, right](#F1){ref-type="fig"}). Focal accumulation of FCV in the prostate gland tumour; and no lymphadenopathy.

However, due to low levels of PSA (0.22 in October 2018), a second reading of histology from the lung tumour was requested. This proved positivity for chromogranin, with the conclusion of possible grade I typical carcinoid; however, the examination was limited due to a lack of preserved tumorous tissue.

Subsequently, a biopsy from the liver metastasis was performed, proving the same type of tumour as in the lungs after the second reading of histology, that is, neuroendocrine tumour (NET) grade 1--2. The patient underwent octreotide SPECT/CT (Fig. [2](#F2){ref-type="fig"}) in December 2018 with the following results: pathological cumulation of radiopharmaceutical in all stages (after 4 and 24 h) found in the area of the left pulmonary hilus, in all three liver metastases, in the bone metastases in the fourth and seventh thoracic vertebrae, the third rib on the right, and in the left ilium.

Significant laboratory results include a chromogranin A level of 109 μg/L in serum, a hydroxyindole acetic acid level of 84.4 μmol/L in urine, and a hydroxyindole acetic acid level of 211 μmol/L in 24-h urine collection (2,500 mL).

The patient is now on therapy with somatostatin analogue.

Discussion/Conclusion {#sec1_3}
=====================

In their paper, Schuster et al. \[[@B9]\] gave an extensive overview of both physiological uptake of FCV as well as incidental uptake, including inflammations and other cancer types; NET, however, is not listed.

We believe that LAT-1 is what interconnects FCV and NET in our patient. LAT-1 expression in healthy adults is detected in the gastrointestinal mucosa, pancreatic islet cells, testicular Sertoli cells, and others \[[@B10]\]. It is overexpressed in some NET, such as pheochromocytoma, medullary thyroid carcinoma, and NET of the lungs. Its overexpression was proven in many types of solid tumours \[[@B11], [@B12], [@B13]\]. Our patient was diagnosed with grade I NET; however, in a study by Kaira et al. \[[@B13]\], all 10 patients diagnosed with grade I NET of the lung did not express LAT-1. Moreover, in a case study presented by Bosserman et al. \[[@B14]\], the authors describe a distinct imaging characteristics, i.e., the uptake of FCV and 68Ga-DOTATATE, in a patient with a history of histologically proven prostate cancer and rectal well-defined NET.

On the other hand, a case presented by Chen et al. \[[@B15]\] describes a patient with low PSA levels and a FCV PET/CT superscan with bone metastases confirmed by biopsy later.

In conclusion, incidental FCV uptake in cancer types other than prostate cancer has already been described, with our case report adding to this list. FCV PET is a tool to detect recurrent prostate cancer with rising PSA levels. In our case, the patient had low PSA levels and FCV uptake in metastases which were later proven to be NET.
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